BLOG

CheckRare

CAMP4 Therapeutics’ Programs For Urea Cycle Disorders and SYNGAP1

CAMP4 is currently working on CMP-CPS-001, a novel investigational therapy designed to address the underlying cause of urea cycle disorders (UCDs) by regulating genes associated with the condition. The first clinical trial of this program was initiated in March 2024 with a phase 1 single-ascending dose study in healthy volunteers. Following the completion of this trial, a multiple-ascending dose study was initiated.